ImmunityBio (IBRX) Provides Update on BLA for N-803

ImmunityBio (NASDAQ: IBRX) continues to explore partnering with a large biopharmaceutical co for commercialization of N-803 for administration intravesically.

• continues to engage in ongoing discussions and dialogue with FDA, including proposed label for product candidate under review in BLA.
• remains unclear if FDA will approve our BLA on PDUFA action date, if at all.
• intends to continue to explore opportunities to engage in incremental financing transactions.

You May Also Be Interested In

• FDA advisory panel votes 9-0 in favor of Moderna's mRNA flu vaccine
• FDA clears Beam Therapeutics IND for PKU gene editing therapy
• FDA accepts Genentech's application for Lunsumio and Polivy combo